Monday, February 8, 2016

Diabetes drug landscape has changed around GlaxoSmithKline's Avandia

GlaxoSmithKline got a small victory Thursday from an FDA advisory committee regarding Avandia, but the diabetes drug market has changed a lot since the drug had $3 billion in sales in 2006.

Diabetes drug landscape has changed around GlaxoSmithKline's Avandia

Glaxo´s type 2 diabetes drug Avandia.
Glaxo's type 2 diabetes drug Avandia.

GlaxoSmithKline got a small victory Thursday when much of a Food and Drug Administration advisory committee urged modifications of the very stringent warnings on the label for its type 2 diabetes drug Avandia.

Those warnings were borne of concerns that the drug caused increased chances of heart attacks. A link to Friday's Inquirer story is here.

But the diabetes drug world has changed a lot since Avandia reached its heights in use and revenue, which was 2006, when it had more than $3 billion in sales.

In 2011, Avandia sales were $513.7 million, but that figure slid to $$265.4 million in 2012, according to the GSK annual report (link here).

The world population of type 2 diabetics has grown and other drug companies have rushed to sell medicine to those people. There are many slices of that market and many drugs. Use of statins to cut cholesterol and, thereby control heart disease, has also increased.

GSK first got approval for the drug in 1999. The patent has expired, GSK no longer promotes the drug and Teva Pharmaceuticals got approval on Jan. 25 of this year to sell a generic version of the drug. A link to the Teva Orange Book page for this drug is here.

GSK is based in London, but has operations in and around Philadelphia. Teva is based in Israel and has facilities in Montgomery and Bucks Counties.

One thing not impacted by Thursday's decision is the legal liabilities GSK still faces. It paid $3 billion in 2012 to settle federal charges, including guilty pleas on three criminal counts, one of which related to withholding safety information about Avandia. But there is lot of Avandia litigation left.

From the 2012 annual report is this passage, which only related to the litigation in two different Philadelphia courts:

"The Group has been named in product liability lawsuits on behalf of individuals asserting personal injury claims arising out of the use of Avandia. The federal cases filed against the Group are part of a multi-district litigation proceeding pending in the United States District Court for the Eastern District of Pennsylvania. Cases have also been filed in a number of state courts. Cases filed in state court in Philadelphia have been coordinated in the Mass Tort Program."


Staff Writer
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at or 215-854-4506.

David Sell Staff Writer
Also on
letter icon Newsletter